Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Silo Pharma (SILO) Income from Continuing Operations (2019 - 2025)

Silo Pharma (SILO) has disclosed Income from Continuing Operations for 7 consecutive years, with 881530.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 49.06% to 881530.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 4227698.0 through Dec 2025, up 3.76% year-over-year, with the annual reading at 4227698.0 for FY2025, 3.76% up from the prior year.
  • Income from Continuing Operations hit 881530.0 in Q4 2025 for Silo Pharma, up from 1110438.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 6472438.0 in Q3 2021 to a low of 1812792.0 in Q1 2023.
  • Historically, Income from Continuing Operations has averaged 675562.3 across 5 years, with a median of 998098.5 in 2022.
  • Biggest YoY gain for Income from Continuing Operations was 1263.13% in 2021; the steepest drop was 261.66% in 2021.
  • Year by year, Income from Continuing Operations stood at 1062788.0 in 2021, then tumbled by 56.46% to 1662831.0 in 2022, then surged by 36.76% to 1051576.0 in 2023, then plummeted by 64.57% to 1730620.0 in 2024, then skyrocketed by 49.06% to 881530.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for SILO at 881530.0 in Q4 2025, 1110438.0 in Q3 2025, and 1204293.0 in Q2 2025.